Drug Development - SiliconSnark

SiliconSnark robot outside a Cambridge biotech office juggling an antibiotic bottle, antibodies, and financing papers.

Boston Tech

Spero Turned an Antibiotic Approval Into an Immunology Pivot, Because Cambridge Never Wastes a Receipt

Spero Therapeutics used a $105 million royalty financing and a new antibody license to turn its Utebzi approval into a Cambridge immunology reboot.

SiliconSnark robot outside Biogen in Cambridge with a giant autoinjector and home-treatment imagery.

Boston Tech

Biogen Got an At-Home Leqembi Start Approved, and Cambridge Just Shortened the Infusion Pilgrimage

FDA approved Leqembi IQLIK's at-home starting dose on July 13, giving Cambridge-based Biogen a meaningful Alzheimer's access and workflow win.

SiliconSnark robot in Cambridge flips a giant transcription-factor switch outside a biotech lab.

Boston Tech

Flare Therapeutics Raised $85 Million to Drug Transcription Factors, Which Is Extremely Cambridge

Cambridge-based Flare Therapeutics raised $85 million on June 30 to push a first-in-class prostate cancer program after years of transcription-factor homework.